Aurobindo Pharma jumps on planning to launch 50-60 new products in US in FY21

23 Jun 2020 Evaluate
Aurobindo Pharma is currently trading at Rs. 810.00, up by 23.60 points or 3.00% from its previous closing of Rs. 786.40 on the BSE.

The scrip opened at Rs. 787.00 and has touched a high and low of Rs. 816.50 and Rs. 787.00 respectively. So far 115699 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 816.50 on 23-Jun-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 816.50 and Rs. 770.00 respectively. The current market cap of the company is Rs. 47507.90 crore.

The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 34.82% and 13.16% respectively.

Aurobindo Pharma is planning to launch 50 to 60 new products in US in FY21. The company has received final approval for six ANDAs (Abbreviated New Drug Application) and launched four products in the fourth quarter of last fiscal. For the full year, it has received approval for 22 ANDAs and launched 34 products across oral, injectable and OTC segments.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1178.20 -7.30 (-0.62%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×